IDIBAPSInstitut d'Investigacions Biomèdiques August Pi i Sunyer (Catalan; Spanish biomedical research institute)
References in periodicals archive ?
8226; NeuroAdvan, the Phase IIa clinical trial, will be led by Dr Pablo Villoslada, director of Neuroimmunology at IDIBAPS, Hospital Clinic de Barcelona, ?
ET in Section 29 Lead Author: Silvia Xargay-Torrent, IDIBAPS, Barcelona, Spain
1] Servei Immunologia, [2] Servei de Toxicologia, and [3] Unitat de Trasplantament Renal, IDIBAPS, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.
Francisco Cervantes, Hematology Department, Hospital ClE[degrees]nic, IDIBAPS, University of Barcelona.
1) Porphyria Unit, Department of Dermatology, Hospital Clinic, IDIBAPS, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; (2) Respiratory and Environmental Research Unit, Institut Municipal d'Investigacion Medica, Universitat Autonoma de Barcelona, Barcelona, Spain; (3) Toxicology Unit, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain; (4) Department of Environmental Chemistry, ICER-CSIC, Barcelona, Spain
1] Servei lmmunologia [2] Toxicologia [3] Unitat de Transplantament Renal, IDIBAPS, Hospital Clinic, C/Villarroel 170, 08036 Barcelona, Spain.